(Valeant) under the Companys License Agreement with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to the Companys EyeGate II Delivery System and EGP-437 combination product (the Product) in the field of uveitis, as well as a right of last negotiation to license the Product for other indications. Under the License Agreement, the Company is eligible to receive milestone payments totaling up to $32.5 million upon and subject to the achievement of certain specified development-based and commercial milestones. Stephen From, President and Chief Executive Officer of EyeGate Pharmaceuticals commented, We are delighted with the progress we have made with the development of EGP-437 in uveitis, evidenced by this latest milestone payment under the Valeant agreement. The further advancement of EGP-437 not only in uveitis, but indications such as macular edema and post-cataract surgery pain and inflammation is an important driver of our future growth. We look forward to ongoing collaboration with Valeant in uveitis and to the continued independent development of EGP-437 in other indications. About EyeGate: EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. The EGP-437 combination product, EyeGates first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGates proprietary innovative drug delivery system, the EyeGate II Delivery System. In addition, EyeGate is developing, through its wholly-owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S), a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. EyeGate intends to initiate a clinical study for Jades lead product candidate for corneal epithelial defects by year-end 2016. For more information, please visit www.EyeGatePharma.com . Safe Harbor Statement: Some of the statements in this press release are forward-looking and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGates products, including EyeGates EGP-437 combination product and those of Jade, a wholly owned subsidiary of EyeGate, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading Risk Factors contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2016, and our Quarterly Report on Form 10-Q, as filed with the SEC on August 10, 2016 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/eyegate-receives-additional-milestone-payment-123000236.html
Lesults of the First International Workshop, Am J Ophthalmology 1403: 509-16, 2005. Anterior uveitis – The most common form of uveitis accounting for 40-70% of cases, it affects the iris and its surrounding tissue, the biliary body. It is often called choroditis or chorioretinitis. Richard H inert, DO Professor of Emergency Megicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Vice-Chair in Charge of Research, Department of Emergency Medicine, Kings County Hospital enter Richard H inert, DO is a member of the following medical societies: American College of Physicians, Society for Academic Emergency Medicine Disclosure: Nothing to disclose. Ophthalmology. no dataWhich part of my eye is affected? Real-world Astigmatism Programs Information | Guidance For The EyeIn addition, your physician probably will ask you about your medical history, and will examine you. Conventionally-treated patients were initially given high doses of prednisone, a corticosteroid medication, for 1 to 4 weeks which were then reduced gradually to low doses whereas locally-treated patients had a capsule that slowly released fluocinolone, another corticosteroid medication, surgically inserted in their affected eyes. Extraocular movement is generally normal. In some cases a corticosteroid medication may be given by injection or in pill form. Symptoms of uveitis can affect one or both eyes. Rev Med Internet. 2009 Hun. 306:492-500. Exp Eye Res. 2002;754:421-30. van Rooij J, Schwartzenberg G, Mulder PG, Baarsma G. Steroids and other immunosuppressants can produce many serious side effects, such as kidney damage, high blood sugar, high blood pressure, osteoporosis and glaucoma.
fainter practices general ophthalmology including cataract surgery and management of corneal and anterior segment diseases. Uveitis and other intra ocular inflammations. homoeopathic remedies have not been studied scientifically for uveitis. This type of uveitis usually occurs in people with an infection from a virus, parasite, or fungus. However, it may be linked to Cohn’s disease and possibly multiple sclerosis. shied Dr., MD, face, face William C. Blumenthal M, Goldberg A, Brinckmann J, eds. Oral corticosteroids tablets or capsules are the strongest form of corticosteroids. Yuan B, et al. Complications of medications, specifically topical steroids, may include glaucoma, cataracts, and potential vision deterioration. 1, 13 Contributor Information and Disclosures Monalisa N Muchatuta, MD, MS Resident Physician, Clinical Assistant Instructor, Department of Emergency Medicine, Kings County Hospital, State University of New York downstage Medical enter Monalisa N Muchatuta, MD, MS is a member of the following medical societies: African Federation for Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Society for Clinical Pathology, Emergency Medicine Residents’ Association, Global Humanitarian Health Association, International Federation for Emergency Medicine, National Medical Association Disclosure: Nothing to disclose.